Diagnosing Autoimmune Psychosis

Why It Matters

Identifying and treating autoimmune contributions to psychosis could transform outcomes for a sizable patient population, shifting care from chronic antipsychotic regimens to targeted immunotherapies.

Key Takeaways

• Up to 30% of psychosis may have autoimmune basis
• Early immunotherapy can reverse symptoms in suspected autoimmune psychosis
• Neurologist‑psychiatrist collaboration essential for accurate diagnosis
• Current antibody panels miss many pathogenic auto‑antibodies in patients
• Heterogeneous schizophrenia likely involves multiple genetic and environmental pathways

Summary

The video explores the emerging field of autoimmune psychosis, arguing that a substantial subset of schizophrenia‑like illnesses may stem from immune dysregulation. Dr. Charlie Marmer and Dr. Caitlyn Nmani discuss recent research suggesting roughly thirty percent of patients could have a treatable autoimmune component, based on novel auto‑antibody discoveries and brain‑slice staining patterns.

Key insights include the diagnostic difficulty of these cases: patients often present with classic psychiatric symptoms before subtle neurological signs appear. Standard MRI, EEG, and antibody panels frequently return normal, yet clinicians can identify red flags such as rapid onset, headache, fluctuating consciousness, and poor response to antipsychotics. In a highlighted case, a young graduate student with acute psychosis received IVIG and steroids despite negative panels, leading to rapid symptom resolution.

Both doctors emphasize the value of dual training; a neurologist‑psychiatrist can integrate psychiatric and neurological cues to suspect an immune‑mediated process. They note that current biomarker panels test only a dozen known antibodies, while many pathogenic antibodies remain undiscovered, underscoring the need for broader assays and interdisciplinary collaboration.

The implications are profound: earlier recognition and immunotherapy could prevent years of ineffective treatment, reduce medication side‑effects, and limit irreversible neural damage. Expanding research into auto‑antibodies and network‑level brain effects may reshape schizophrenia classification, offering a new therapeutic avenue for a disorder long considered untreatable for many patients.

Original Description

Katlyn Nemani, MD, explores how autoimmune and inflammatory brain disorders can present as first-episode psychosis—and why some patients diagnosed with schizophrenia may actually have a treatable immune-mediated illness. She explains the clinical features that should prompt suspicion for autoimmune psychosis, including subacute onset, subtle neurologic signs, and poor response to antipsychotics, even when standard imaging and antibody tests are unrevealing.

Dr. Nemani also discusses the limits of current biomarkers, how to think clinically when diagnostic certainty is incomplete, and why early immunotherapy can dramatically alter outcomes. The conversation closes with a forward-looking discussion of emerging research suggesting that a meaningful subset of schizophrenia-like illness may ultimately be reclassified as autoimmune in origin.

Katlyn Nemani, MD, is a Research Assistant Professor in the Departments of Psychiatry and Neurology at NYU Grossman School of Medicine and a graduate of NYU’s combined Neurology-Psychiatry residency program.

▶️ Watch Insights on Psychiatry on YouTube

00:00 When Psychosis May Be an Autoimmune Disease

01:18 Early Psychiatric Symptoms of Autoimmune Encephalitis

02:47 Why Subtle Neurologic Clues Matter

04:00 A Case of Rapidly Reversible Psychosis

06:37 The Limits of Antibody Testing

07:51 Why Early Treatment Changes Outcomes

08:18 Rethinking the Heterogeneity of Schizophrenia

09:31 How Common Is Autoimmune Contribution to Psychosis?

10:48 Network-Level Brain Effects and Open Research Questions

This episode is intended for psychiatrists, neurologists, and other clinicians interested in psychosis, neuroinflammation, and complex diagnostic presentations at the psychiatry–neurology interface.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

ABOUT THE EXPERTS: 

Charles R. Marmar, MD: https://nyulangone.org/doctors/1962502054/charles-r-marmar

Shu Professor of Psychiatry

Director, Center for Precision Psychiatry

NYU Grossman School of Medicine 

Katlyn Nemani: https://nyulangone.org/doctors/1598176315/katlyn-nemani

Research Assistant Professor, Department of Psychiatry at NYU Grossman School of Medicine

Subscribe for more clinical innovations from NYU Langone Health